KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Receivables - Net: 2017-2025

Historic Receivables - Net for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $1.4 billion.

  • Amneal Pharmaceuticals' Receivables - Net rose 19.05% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 19.05%. This contributed to the annual value of $1.3 billion for FY2024, which is 8.65% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Receivables - Net stood at $1.4 billion for Q3 2025, which was up 7.93% from $1.3 billion recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Receivables - Net peaked at $1.4 billion during Q3 2025, and registered a low of $933.6 million during Q1 2022.
  • Its 3-year average for Receivables - Net is $1.2 billion, with a median of $1.2 billion in 2024.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Receivables - Net decreased by 25.41% in 2021 and then increased by 19.05% in 2025.
  • Amneal Pharmaceuticals' Receivables - Net (Quarterly) stood at $1.2 billion in 2021, then increased by 12.85% to $1.3 billion in 2022, then decreased by 10.78% to $1.2 billion in 2023, then climbed by 8.65% to $1.3 billion in 2024, then climbed by 19.05% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.3 billion for Q2 2025, and $1.3 billion during Q1 2025.